Kezar Life Sciences regains Nasdaq compliance as stock price holds above $1.00

Kezar Life Sciences, Inc.

Received Nasdaq Staff letter on Nov 13, 2024 confirming regained compliance.
Closing bid price was $1.00 or greater for 10 consecutive business days through Nov 13.
Now compliant with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.
Resolves prior deficiency; no further action required from the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.